Cefuroxime Pediatric Dosing
Cefuroxime is an alternative second-line agent for pediatric pneumonia, with oral dosing of cefuroxime (cefpodoxime, cefprozil) listed as alternatives to amoxicillin for step-down therapy in community-acquired pneumonia, though it is not a preferred first-line agent. 1
Oral Dosing (Cefuroxime Axetil)
Community-Acquired Pneumonia
The oral suspension formulation allows for sequential IV-to-oral therapy, with studies demonstrating 30 mg/kg/day divided twice daily is effective following initial parenteral therapy 3. This approach achieved 97.6% cure/improvement rates in children under 5 years with lobar pneumonia.
Urinary Tract Infections
Short-course therapy (2 days) with cefuroxime axetil 125 mg twice daily showed comparable efficacy to 10-day courses for uncomplicated UTIs in children 2-11 years 4, though conventional 7-10 day courses remain standard practice.
Intravenous/Intramuscular Dosing
Standard Infections
- 20-30 mg/kg every 8 hours (TID) for most infections 2
- Maximum daily dose typically 6 grams in adults
Severe Pneumonia
75 mg/kg/day divided every 8 hours IV/IM was the regimen validated in clinical trials for bacterial pneumonia 5. This achieved mean serum concentrations of 29.1 mcg/mL 30 minutes post-infusion with a 25 mg/kg dose, providing adequate coverage for S. pneumoniae, H. influenzae, and S. aureus.
Neonatal Dosing
50 mg/kg twice daily (every 12 hours) IM or IV for neonates 6. This regimen accounts for prolonged half-life in neonates:
- <4 days old: Mean half-life 5.8 hours
- >8 days old: Half-life 1.6-3.8 hours
Peak levels after IM injection averaged 42.7 mg/L with trough levels of 10.5 mg/L, providing adequate coverage without toxicity.
Surgical Prophylaxis (Cardiac Surgery)
For infants undergoing cardiopulmonary bypass: 50 mg/kg IV after induction, followed by 75 mg/kg into the CPB circuit 7. Alternative continuous dosing: 25 mg/kg bolus plus 5 mg/kg/hour infusion maintains concentrations >32 mcg/mL throughout the procedure.
Clinical Context and Limitations
Important caveat: Cefuroxime is listed only as an alternative oral agent for pneumonia step-down therapy in the IDSA/PIDS guidelines 1. The preferred agents remain:
- Amoxicillin for penicillin-susceptible S. pneumoniae
- Third-generation cephalosporins (ceftriaxone/cefotaxime) for resistant organisms or severe infections
Pharmacokinetic Considerations
- Protein binding: 33-50% 8, 9
- Renal excretion: 89% unchanged in urine over 8 hours 8
- Bioavailability (oral): 68% (tablets), enhanced with food 9
- Half-life: Approximately 80 minutes in older children/adults 8
Coverage Gaps
Cefuroxime has limited activity against:
- Highly penicillin-resistant S. pneumoniae (MIC ≥4 mcg/mL)
- Atypical pathogens (Mycoplasma, Chlamydophila)
- MRSA
- Many gram-negative rods beyond H. influenzae
For these pathogens, alternative agents are required per guidelines 1.
Renal Dose Adjustments
While specific pediatric renal dosing is not detailed in the provided evidence, adult data suggests dose reduction is necessary when creatinine clearance falls below 20 mL/min 8. In critically ill children with augmented renal clearance, standard dosing may be inadequate - though this is better documented for cefotaxime than cefuroxime 10.
Treatment Duration
- Pneumonia: 5-7 days total (including IV-to-oral transition) 3
- UTI: 2-10 days depending on severity 4
- Surgical prophylaxis: Single perioperative dose or 24-48 hours maximum
The shortest effective duration minimizes antimicrobial resistance selection 1.
Adverse Effects
Generally mild and transient 9: